# GeneMorph® II EZClone Domain Mutagenesis Kit

## **INSTRUCTION MANUAL**

Catalog #200552 Revision A

## **LIMITED PRODUCT WARRANTY**

This warranty limits our liability to replacement of this product. No other warranties of any kind, express or implied, including without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Stratagene. Stratagene shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

### **ORDERING INFORMATION AND TECHNICAL SERVICES**

#### **United States and Canada**

#### Stratagene

11011 North Torrey Pines Road

La Jolla, CA 92037

 Telephone
 (858) 373-6300

 Order Toll Free
 (800) 424-5444

 Technical Services
 (800) 894-1304

**Internet** tech\_services@stratagene.com

World Wide Web www.stratagene.com

## **Stratagene European Contacts**

| Location       | Telephone       | Fax                | Technical Services |
|----------------|-----------------|--------------------|--------------------|
| Austria        | 0800 292 499    | 0800 292 496       | 0800 292 498       |
| Belgium        | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 15775      | 0800 15740         | 0800 15720         |
| France         | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 919 288    | 0800 919 287       | 0800 919 289       |
| Germany        | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 182 8232   | 0800 182 8231      | 0800 182 8234      |
| Netherlands    | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 023 0446   | +31 (0)20 312 5700 | 0800 023 0448      |
| Switzerland    | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 563 080    | 0800 563 082       | 0800 563 081       |
| United Kingdom | 00800 7000 7000 | 00800 7001 7001    | 00800 7400 7400    |
|                | 0800 917 3282   | 0800 917 3283      | 0800 917 3281      |

#### **All Other Countries**

Please contact your local distributor. A complete list of distributors is available at www.stratagene.com.

# GeneMorph® II EZClone Domain Mutagenesis Kit

## **CONTENTS**

| Materials Provided                               | 1  |
|--|----|
| Storage Conditions                               | 1  |
| Additional Materials Required                    | 1  |
| Introduction                                     | 2  |
| Eliminate Bias and Easily Control Mutation Rate  | 4  |
| EZClone Reaction                                 | 8  |
| GeneMorph® II EZClone Domain Mutagenesis Control | 9  |
| XL10-Gold® Ultracompetent Cells                  | 9  |
| Preprotocol Considerations                       | 10 |
| Mutant Megaprimer Synthesis Considerations       | 10 |
| EZClone Reaction Considerations                  | 12 |
| Protocol   | 13 |
| Mutant Megaprimer Synthesis                      | 13 |
| EZClone Reaction                                 | 16 |
| Expected Results                                 | 20 |
| Transformation Guidelines                        | 21 |
| Troubleshooting                                  | 22 |
| Preparation of Media and Reagents                | 24 |
| Appendix: How to Calculate Mutation Frequency    | 25 |
| References                                       | 27 |
| Endnotes   | 27 |
| MSDS Information                                 | 27 |
| Ouick-Reference Protocol                         | 29 |

## GeneMorph® II EZClone Domain Mutagenesis Kit

#### MATERIALS PROVIDED

| Materials provided <sup>a</sup>                               | Concentration   | Quantity   |
|---|-----------------|------------|
| Mutazyme® II DNA polymerase <sup>b</sup>                      | 2.5 U/μl        | 25 U       |
| 10× Mutazyme® II reaction buffer                              | 10×             | 150 μΙ     |
| 40 mM dNTP mix <sup>c</sup>                                   | 10 mM each dNTP | 10 μΙ      |
| 2× EZClone enzyme mix   | 2×              | 250 μΙ     |
| Dpn I restriction enzyme                                      | 10 U/μΙ         | 100 U      |
| EZClone solution  | _               | 30 μΙ      |
| Positive control plasmid                                      | 10 ng/μl        | 210 ng     |
| Positive control primer mix                                   | 250 ng/μl       | 750 ng     |
| 1.1-kb gel standard   | 20 ng/μl        | 50 μΙ      |
| XL10-Gold® ultracompetent cells <sup>d,e</sup> (yellow tubes) | _               | 4 × 135 μl |
| XL10-Gold® β-mercaptoethanol mix (β-ME)                       | _               | 50 μΙ      |
| pUC18 control plasmid (0.1 ng/μl in TE buffer¹)               | 0.1 ng/μl       | 10 μΙ      |

<sup>&</sup>lt;sup>a</sup> Sufficient reagents are provided for 10 reactions, which includes 3 control reactions.

## **STORAGE CONDITIONS**

**XL10-Gold® ultracompetent cells:** Store the cells immediately at -80°C.

Do not place the cells in liquid nitrogen.

All other components: Store at  $-20^{\circ}$ C upon receipt. Store the 2× EZClone enzyme mix at 4°C after thawing. Once thawed, full activity is guaranteed for 3 months.

## **ADDITIONAL MATERIALS REQUIRED**

Temperature cycler

PCR tubes||

PCR primers

14-ml BD Falcon polypropylene round-bottom tubes (BD Biosciences Catalog #352059)

Revision A

Copyright © 2007 by Stratagene.

<sup>&</sup>lt;sup>b</sup> Mutazyme<sup>®</sup> II DNA polymerase is not sold separately.

<sup>&</sup>lt;sup>c</sup> Thaw the dNTP mix once, prepare single-use aliquots, and store the aliquots at –20°C. Do not subject the dNTP mix to multiple freeze-thaw cycles.

Genotype: Tet'Δ (mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F' proAB lacl<sup>Q</sup>ZΔM15 Tn10 (Tet') Amy Cam<sup>r</sup>]

The XL10-Gold® ultracompetent cells must be stored at the bottom of a -80°C freezer immediately on receipt. The ultracompetent cells are very sensitive to small variations in temperature. Transferring tubes from one freezer to another may result in a loss of efficiency.

<sup>&</sup>lt;sup>f</sup> The pUC18 control plasmid is stored in TE buffer (see Preparation of Media and Reagents).

Thin-walled PCR tubes are highly recommended for use with Stratagene's thermal cyclers. These PCR tubes are optimized to ensure ideal contact with the multiblock design to permit more efficient heat transfer and to maximize temperature cycling performance.

#### INTRODUCTION

Random mutagenesis is a powerful tool for elucidating protein structurefunction relationships and for modifying proteins to improve or alter their characteristics. Error-prone PCR is a random mutagenesis technique for generating amino acid substitutions in proteins, domains or promoter elements by introducing mutations during PCR. However, cloning amplicons generated by error-prone PCR can be difficult and labor-intensive due to low product yields, mutations at the ends which interfere with restriction-based cloning, and/or inefficient synthesis of 3' dA overhangs or blunt ends which reduces the efficiency of TA- or blunt-end cloning strategies. In addition, targeting specific functional domains for random mutagenesis can also be difficult and inefficient using current methods. To address the need for efficient and flexible cloning methods, the GeneMorph® II EZClone domain mutagenesis kit\* offers an easy and fast cloning method to perform targeted random mutagenesis on protein domains and promoter elements, while delivering a uniform mutational spectrum. Utilizing a unique cloning method, the GeneMorph II EZClone kit allows you to target specific protein domains or promoter elements without the need for restriction sites or sub-cloning (see Figure 1).<sup>1,2</sup>


The kit contains Mutazyme® II DNA polymerase, which deliberately introduces mutations during PCR with a more uniform mutational spectrum compared to other error-prone PCR enzymes. Additionally, this kit includes an optimized reaction buffer for the error-prone PCR step so that you need only vary the input DNA amount added to the reaction to produce the desired mutational frequency. The resulting purified mutated PCR products serve as megaprimers for the EZClone reaction\*\* during which they are denatured and annealed to the original donor plasmid and extended with a specialized enzyme mix containing a high fidelity DNA polymerase. Using a high-fidelity polymerase minimizes unwanted secondary mutations during cloning process, which can affect downstream The EZClone reaction is temperature cycled several times before being treated with a unique enzyme to remove parental DNA prior to transformation into competent E. coli. Our XL10-Gold® ultracompetent cells are included to maximize library size and diversity. Screening libraries created by random mutagenesis allows researchers to identify beneficial mutations in the absence of structural information, or when such mutations are difficult to predict from protein structure.<sup>3</sup>

<sup>\*</sup> U.S. Patent Nos. 6,803,216, 5,489,523, and patent pending

<sup>\*\*</sup> U.S. Patent Nos. 6,713,285, 6,391,548, 5,789,166 and 5,932,419, and patents pending.

# GeneMorph®II EZClone Method

#### **Mutant Megaprimer Synthesis**



Amplify gene or gene fragment using Mutazyme®II DNA Polymerase




X XX

Purify target fragment containing mutations (X)


#### **EZClone Reaction**



Mutated PCR products serve as megaprimers that are denatured and annealed to the original donor plasmid and extended in the EZClone reaction using a specialized high fidelity enzyme mix



EZClone restriction enzyme *Dpn* I digests unmutated donor plasmid DNA



Plasmids with mutations in targeted gene or gene fragment are transformed into competent *E. coli* cells

**FIGURE 1** GeneMorph® II EZClone domain mutagenesis kit method.

## **Eliminate Bias and Easily Control Mutation Rate**

The mutational bias exhibited by error-prone PCR enzymes undoubtedly skews representation of random mutant libraries, diminishing the effective size of the collection produced by error-prone PCR. Mutazyme II DNA polymerase is a novel error-prone PCR enzyme blend, formulated to provide useful mutation rates with minimal mutational bias. Mutazyme II is a blend of two error-prone DNA polymerases—Mutazyme I DNA polymerase (from the GeneMorph Random Mutagenesis Kit) and a novel Taq DNA polymerase mutant that exhibits increased misinsertion and misextension frequencies compared to wild type Taq. For the Mutazyme II polymerase formulation, the Mutazyme I polymerase and the Taq polymerase mutant have been combined to produce a less biased mutational spectrum with equivalent mutation rates at A's and T's vs. G's and C's. Therefore, libraries created with Mutazyme II exhibit greater mutant representation compared to libraries generated with other enzymes.

With the GeneMorph II EZClone kit, mutation rates of 1–16 mutations per kb can be achieved using the provided buffer, which is optimized for high product yield. The desired mutation rate can be controlled simply by varying the initial amount of target DNA in the reaction or the number of amplification cycles performed.

#### **How Mutation Frequency is Controlled**

Mutation frequency is the product of DNA polymerase error rate and number of duplications (see Appendix). In the GeneMorph II EZClone kit, a sufficiently high error rate is achieved through use of Mutazyme II DNA polymerase. A low, medium or high mutation frequency is produced by adjusting the initial target DNA amounts in the amplification reactions. For the same PCR yield, targets amplified from low amounts of target DNA undergo more duplications than targets amplified from high concentrations of DNA. The more times a target is replicated, the more errors accumulate. Therefore, higher mutation frequencies are achieved simply by lowering input DNA template concentration. Conversely, lower PCR mutation frequencies can be achieved by using higher DNA template concentrations to limit the number of target duplications. Mutation rates can also be decreased by lowering the number of cycles to achieve fewer target duplications. For targets that produce high product yields after 30 cycles, lower mutation rates can be achieved by amplifying lower target amounts for 20-25 cycles.

#### **Selecting the Appropriate Mutation Frequency**

The GeneMorph II EZClone kit allows researchers to choose the mutation frequency that is most appropriate for a particular application. For analyzing protein structure-function relationships, the desired mutation frequency is one amino acid change (1–2 nucleotide changes) per gene.<sup>4</sup> In directed evolution studies, mutation frequencies of 1–4 amino acid changes (2–7 nucleotide changes) per gene are commonly employed.<sup>5–8</sup> Proteins with improved activities have also been isolated from highly mutagenized libraries exhibiting 20 mutations per gene.<sup>3</sup>

#### **Achieving the Desired Mutation Frequency**

Table I presents the initial amount of target DNA required to produce low, medium, or high mutation frequencies. An initial target amount of 500-1000 ng is recommended to achieve low mutation frequencies of 0-4.5 mutations/kb. Low mutation frequencies can also be achieved by using 100-500 ng of target DNA with a lower number of PCR cycles (see Cycle Number in Preprotocol Considerations). Initial target amounts ranging from 100-500 ng are recommended for producing mutation frequencies of 4.5–9 mutations/kb (medium mutation frequency range). High mutation frequencies (>9 mutations/kb) are obtained by using 0.1-100 ng of input target DNA, where the highest mutation rates can be achieved using the lowest recommended target amounts. Mutation rates up to 16 mutations per kb have been achieved using 0.01 ng of target DNA, although PCR product yields tend to decrease at amounts below 0.1 ng. The predicted mutation frequencies shown in Table I are accurate for amplification reactions producing the indicated approximate fold amplification. The actual number of mutations in individual clones may differ as the values in Table I represent the average mutation frequency for the entire pool of clones.

TABLE I

Mutation Frequency vs. Initial Target Quantity

| Mutation rate | Mutation frequency<br>(mutations/kb)° | Initial target amount (ng) <sup>b,c</sup> | Recommended fold amplification |
|---------------|---------------------------------------|---|--------------------------------|
| Low           | 0–4.5                                 | 500–1000                                  | 1.5–10                         |
| Medium        | 4.5–9                                 | 100–500                                   | 10–100                         |
| High          | 9–16                                  | 0.1–100                                   | 100–10,000                     |

These values are accurate for reactions achieving the approximate fold amplification (total yield/input DNA) indicated. The actual number of mutations in each clone may differ as these values represent the average frequency for all clones.

b The amount of template indicated is the amount of target DNA to be amplified, not the total amount of DNA template to add to the reaction. See *Initial Amount of Target* in *Preprotocol Considerations* for an example on how to calculate initial target amount.

 $<sup>^{\</sup>rm c}$  The recommended DNA target amounts are higher for Mutazyme II compared to Mutazyme I since Mutazyme II exhibits a  $\sim\!\!3\text{-fold}$  higher error rate compared to Mutazyme I.

#### Mutational Spectrum of the GeneMorph® II Kit

The mutational spectra of Mutazyme II DNA polymerase, Mutazyme I DNA polymerase, and *Taq* DNA polymerase (with Mn<sup>2+</sup>-containing buffer and unbalanced dNTP concentrations) are compared in Table II. These errorprone PCR enzymes introduce all possible nucleotide substitutions, however, Mutazyme II DNA polymerase exhibits less mutational bias compared to Mutazyme I and *Taq* DNA polymerases.

There are several ways to assess bias in an enzyme's mutational spectra. Bias can be examined by analyzing the ratio of transition (Ts) to transversion (Tv) mutations produced. Transition mutations are purine (A and G) to purine changes and pyrimidine (C and T) to pyrimidine changes, while transversions are purine to pyrimidine and pyrimidine to purine changes. There are eight possible transversions and four possible transitions, and an enzyme completely lacking bias would exhibit a Ts/Tv ratio of 0.5. Secondly, mutational bias has been assessed by calculating the ratio of AT→GC to GC→AT transition mutations (AT→GC/GC→AT ratio), which would equal 1 for a completely unbiased enzyme. Thirdly, mutational bias can be assessed by comparing the frequency of mutating A's and T's vs. the frequency of mutating G's and C's (AT→NN/GC→NN ratio), which should be equal for an unbiased DNA polymerase.

The *Taq* DNA polymerase was used in the PCR with Mn<sup>2+</sup>-containing buffer and unbalanced deoxynucleotide concentrations, which are mutagenic conditions for *Taq* DNA polymerase.

TABLE II

Mutational Spectra of Mutazyme and Taq DNA Polymerases

| Type(s) of mutations                  | Mutazyme® II<br>DNA polymeraseª | Mutazyme® I<br>DNA polymeraseª | Taq DNA polymerase<br>(Reference 5) <sup>b</sup> |
|---------------------------------------|---------------------------------|--------------------------------|--|
| Bias Indicators                       |                                 |                                |  |
| Ts/Tv                                 | 0.9                             | 1.2                            | 0.8  |
| AT→GC/GC→AT                           | 0.6                             | 0.2                            | 1.9  |
| A→N, T→N                              | 50.7%                           | 25.6%                          | 75.9%  |
| G→N, C→N                              | 43.8%                           | 72.5%                          | 19.6%  |
| Transitions                           |                                 |                                |  |
| $A \rightarrow G$ , $T \rightarrow C$ | 17.5%                           | 10.3%                          | 27.6%  |
| G→A, C→T                              | 25.5%                           | 43.7%                          | 13.6%  |
| Transversions                         |                                 |                                |  |
| $A \rightarrow T$ , $T \rightarrow A$ | 28.5%                           | 11.1%                          | 40.9%  |
| $A \rightarrow C$ , $T \rightarrow G$ | 4.7%                            | 4.2%                           | 7.3%   |
| G→C, C→G                              | 4.1%                            | 8.8%                           | 1.4%   |
| $G \rightarrow T$ , $C \rightarrow A$ | 14.1%                           | 20.0%                          | 4.5%   |
| Insertions and Deletions              |                                 |                                |  |
| Insertions                            | 0.7%                            | 0.8%                           | 0.3%   |
| Deletions                             | 4.8%                            | 1.1%                           | 4.2%   |
| Mutation Frequency                    |                                 |                                |  |
| Mutations/kb (per PCR) <sup>c</sup>   | 3-16 (per PCR)                  | <1 to 7 (per PCR)              | 4.9 (per PCR)                                    |

- $^{\circ}$  The Mutazyme DNA polymerases were used with the corresponding GeneMorph random mutagenesis kits.
- <sup>b</sup> The Taq DNA polymerase was used with Mn<sup>2+</sup>-containing buffer and unbalanced dNTP concentrations, which are mutagenic conditions for Tag DNA polymerase.
- <sup>c</sup> Initial target amounts of 16 pg to 1 μg (Mutazyme II DNA polymerase), 1 pg to 100 ng (Mutazyme I DNA polymerase), and 0.01 nM template (Taq DNA polymerase) were used to generate data.

As shown in Table II, error-prone enzymes generally favor transitions over transversions, as shown by Ts/Tv ratios greater than 0.5, with Mutazyme II and Taq exhibiting a somewhat higher tendency to create transversions over transitions and Mutazyme I exhibiting a greater tendency for introducing transitions over transversions. Examining transition mutation frequencies shows that Mutazyme II produces  $AT \rightarrow GC$  and  $GC \rightarrow AT$  mutations with similar rates ( $AT \rightarrow GC/GC \rightarrow AT$  ratio = 0.6), while Mutazyme I is 4 times more likely to generate  $GC \rightarrow AT$  transitions over  $AT \rightarrow GC$  transitions, and Taq is 2 times more likely to introduce  $AT \rightarrow GC$  transitions over  $GC \rightarrow AT$  transitions. In addition, Mutazyme II DNA polymerase introduces mutations at A's and T's only slightly more frequently than G's and C's. In contrast, Mutazyme I is nearly 3 times more likely to mutate G's and C's, while Taq under error-prone conditions is 4 times more likely to mutate A's and T's than G's and C's.

The spectrum of mutations produced by the GeneMorph II EZClone kit is the same at all mutation frequencies. With the GeneMorph II EZClone kit, low, medium, and high mutation frequencies are achieved using a single set of buffer conditions (MgCl<sub>2</sub>, balanced dNTPs) optimized for high product yield. The only parameter varied is the initial amount of target DNA in the reaction or the number of cycles employed. In contrast, *Taq* DNA polymerase–based mutagenesis methods typically employ different sets of reaction conditions to vary mutation levels. Varying the buffer conditions (e.g., different Mn<sup>2+</sup> concentrations) and/or the concentrations of one or more nucleotides to alter mutation frequency can lead to changes in *Taq*'s mutational spectrum and increased mutational bias.

Furthermore, mutational hotspots have not been observed in any of the mutagenized genes generated by Mutazyme II DNA polymerase that have been sequenced.<sup>9</sup>

#### **EZClone Reaction**

The EZClone reaction utilizes (1) a supercoiled double-stranded DNA (dsDNA) vector containing the same region targeted for mutagenesis in the mutagenesis reaction and (2) two megaprimers generated in the mutagenesis reaction containing random mutations. The EZClone enzyme mix is a 2× formulation containing a high fidelity DNA polymerase to minimize unwanted second site errors, an optimized PCR reaction buffer, magnesium, and dNTPs. The megaprimers, each complementary to opposite strands of the vector, are extended during temperature cycling by the EZClone enzyme mix, without primer displacement. Extension of the megaprimers generates a mutated plasmid containing staggered nicks. Following temperature cycling, the product is treated with Dpn I restriction enzyme. The Dpn I endonuclease (target sequence: 5'-Gm<sup>6</sup>ATC-3') is specific for methylated and hemimethylated DNA and is used to digest the parental DNA template. Because DNA produced during PCR is not methylated, *Dpn* I selects for the mutation-containing synthesized DNA.<sup>10</sup> The nicked vector DNA incorporating the desired mutations is then transformed into competent cells (provided), where the nicks are repaired by endogenous enzymes in the cell.

**Note** While plasmid DNA isolated from almost all of the commonly used E. coli strains (dam<sup>+</sup>) is methylated and is a suitable template for mutagenesis, plasmid DNA isolated from the exceptional dam<sup>-</sup> E. coli strains, including JM110 and SCS110, is not suitable.

### GENEMORPH® II EZCLONE DOMAIN MUTAGENESIS CONTROL

To demonstrate the effectiveness of the GeneMorph II EZClone method the 3.0-kb positive control plasmid, which contains the *lacZ* gene, is used to test the efficiency of mutant megaprimer synthesis and the EZClone reaction. XL10-Gold ultracompetent cells\* transformed with this control plasmid appear blue on LB–ampicillin agar plates (see *Preparation of Media and Reagents*), containing IPTG and X-gal. Following random mutagenesis and EZCloning, >25% of the colonies plated appear white on LB–ampicillin plates containing IPTG and X-gal because  $\beta$ -galactosidase activity has been obliterated.

### XL10-GOLD® ULTRACOMPETENT CELLS

Stratagene's XL10-Gold ultracompetent cells, a derivative of Stratagene's highest-efficiency competent cell line XL2-Blue MRF', possess the Hte phenotype, which increases transformation efficiency of ligated DNA.<sup>11</sup> XL10-Gold cells are both endonuclease deficient (endA1) and recombination deficient (recA). The endA1 mutation greatly improves the quality of plasmid miniprep DNA, 12 and the *recA* mutation helps ensure insert stability. In addition, the McrA, McrCB, McrF, Mrr, and HsdR systems have been removed from XL10-Gold ultracompetent cells. The mcrA, mcrCB and mrr mutations prevent cleavage of cloned DNA that carries cytosine and/or adenine methylation, which is often present in eukaryotic DNA and cDNA. 13-15 The McrA and McrCB systems recognize and restrict methylated cytosine DNA sequences, and the Mrr system recognizes and restricts methylated adenine DNA sequences. The Mrr system also restricts methylated cytosine DNA sequences with a specificity differing from that of McrA and McrCB. This activity has been named McrF. This McrF activity against methylated cytosines has been shown to be equal to or greater than the restriction activity of the McrA and McrCB systems. 16 The hsdR mutation prevents the cleavage of cloned DNA by the EcoK (hsdR) endonuclease system. XL10-Gold cells grow faster than XL1 or XL2-Blue cells, resulting in larger colonies. To permit blue-white color screening, the XL10-Gold ultracompetent cells contain the  $lacI^qZ\Delta M15$  gene on the F' episome.

| Host strain                        | References | Genotype   |
|------------------------------------|------------|--|
| XL10-Gold®<br>ultracompetent cells | 11, 17, 18 | Tet <sup>R</sup> Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173<br>endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte<br>[F´ proAB lacl <sup>q</sup> ZΔM15 Tn10 (Tet <sup>R</sup> ) Amy Cam <sup>R</sup> ] |

It is important to store the XL10-Gold ultracompetent cells at  $-80^{\circ}$ C to prevent a loss of efficiency. For best results, please follow the directions outlined in the following sections.

<sup>\*</sup> U.S. Patent Nos. 6,706,525, 5,512,468 and 5,707,841 and patents pending and equivalent foreign patents

## PREPROTOCOL CONSIDERATIONS

#### **Mutant Megaprimer Synthesis Considerations**

#### **Amplification Targets**

The GeneMorph II EZClone kit has been used to mutagenize targets up to 3.5 kb in length from plasmid DNA.

Genomic DNA templates are not generally recommended for error-prone PCR as researchers are limited to medium-to-high mutation levels due to the low copy number of genomic DNA targets. If genomic DNA is the only source of the target gene, we recommend amplifying the target with a high-fidelity DNA polymerase, such as *PfuUltra*® high-fidelity DNA polymerase, followed by re-amplification of the diluted PCR product with Mutazyme II DNA polymerase.

#### **Initial Amount of Target DNA**

The mutation frequency depends upon the initial amount of target DNA employed in the reaction. The amount of target to add to a reaction can be determined using Table I.

The initial amount of target DNA required to achieve a particular mutation frequency refers to the amount of target DNA to amplify, not the total amount of plasmid DNA template to add to the reaction. As an example, to mutagenize a 1.0-kb target gene at a low mutation frequency, an initial target amount of 500 ng is recommended. For a 1.0-kb target gene that is an insert in a 3.0-kb plasmid (the total construct is 4.0 kb), 2  $\mu$ g of the plasmid construct should be added to the reaction to provide 500 ng of target DNA.

#### Cycle Number

In addition to using higher target DNA amounts, mutation rates can also be lowered by decreasing the number of cycles employed to achieve fewer target duplications. For targets that produce high product yields after 30 cycles, lower mutation rates can be achieved by amplifying lower target amounts for 20 to 25 cycles (see Table III).

TABLE III

Achieving Low Mutation Frequency Using Fewer Cycle Numbers

| Mutation frequency<br>(mutations/kb) <sup>a</sup> | Cycle Number | Initial target amount <sup>b</sup> |
|---|--------------|------------------------------------|
| 0–4.5 (low range)                                 | 20–25        | 100 ng                             |
|   | 30           | 500 ng-1000 ng                     |

- These values are accurate for reactions achieving the approximate 1.5–10 fold amplification (total yield/input DNA). The actual number of mutations in each clone may differ as these values represent the average frequency for all clones.
- The amount of template indicated is the amount of target DNA to be amplified, not the total amount of DNA template to add to the reaction. See *Initial Amount of Target* in *Preprotocol Considerations* for an example on how to calculate initial target amount.

#### **Primer Design**

Standard PCR primers flanking the region targeted for mutagenesis are used in the mutant megaprimer synthesis reaction. For best results, PCR primers should be designed with similar melting temperatures ranging from 55 to 72°C. The use of primers with melting temperatures within this range reduces false priming and ensures complete denaturation of unextended primers at 94–95°C.

#### **PCR Product Yield**

The PCR product yield should be within the recommended range to obtain the predicted mutation frequencies listed in Tables I and III. To ensure sufficient product yield, sample PCR reactions are electrophoresed adjacent to a DNA standard provided in the kit. PCR product yields are quantified by comparing the staining intensity of PCR product bands to the DNA standard.

#### **Achieving High Mutation Frequencies**

The highest mutation frequency that can be achieved in one round of PCR is limited by the minimum amount of target DNA that can be amplified in high product yield. In the GeneMorph II kit, we recommend using 0.1–100 ng of target DNA, which is sufficient to produce high product yields after 30 cycles and mutation frequencies up to 9–16 mutations per kb of target. Higher mutation frequencies can be achieved by amplifying from <0.1ng target DNA, although product yields may be noticeably lower. Alternatively, mutation frequencies > 20 mutations per kb can be achieved by performing sequential PCRs, in which a small aliquot of the first PCR reaction is re-amplified in a second PCR reaction.

#### **EZClone Reaction Considerations**

#### **Required Host Strain**

Ensure that the plasmid DNA template is isolated from a dam+ *E. coli* strain. The majority of the commonly used *E. coli* strains are dam+. Plasmid DNA isolated from dam– strains (e.g. JM110 and SCS110) is not suitable.

#### **Plasmid DNA Template Guidelines**

The plasmid DNA template used in the EZClone reaction may be the same or different than the original plasmid DNA used as template in the mutant megaprimer synthesis reaction, provided that the region targeted in the mutagenesis reaction is present in the plasmid.

The plasmid DNA template used in the EZClone reaction should be less than 10 kb in length to ensure full extension during temperature cycling.

#### **Mutant Megaprimer Synthesis**

**Note** Gently mix and centrifuge each component before use. Prepare all reactions on ice.

1. Refer to Table I to determine the initial amount of target to use in each reaction.

Note

Target DNA refers to the DNA sequence to be amplified, not the total amount of plasmid DNA in the reaction (see Initial Amount of Target in Preprotocol Considerations).

2. Prepare the control reaction as indicated below:

5 μl of 10× Mutazyme II reaction buffer

2 μl of 0.5 ng/μl positive control plasmid (dilute the control provided 1:20 in high-quality water for a final concentration of 0.5 ng/μl)

1 μl of positive control primer mix (125 ng/μl of each primer)

1 μl of 40 mM dNTP mix (200 μM each final)

40 ul of ddH<sub>2</sub>O

1  $\mu$ l of Mutazyme II DNA polymerase (2.5 U/ $\mu$ l)

3. Prepare the sample reaction(s) as indicated below:

5 μl of 10× Mutazyme II reaction buffer

x µl template (see Table I for recommended amount)

x μl of sample primers (125 ng/μl of each primer)

1 µl of 40 mM dNTP mix (200 µM each final)

x μl of ddH<sub>2</sub>O for a final reaction volume of 50 μl

1 μl of Mutazyme II DNA polymerase (2.5 U/μl)

- 4. Centrifuge each reaction briefly.
- 5. If the thermal cycler does not have a heated lid, overlay each reaction with a few drops of mineral oil.

6. Place each reaction in a temperature cycler. Run one of the following suggested PCR programs, depending on the type of temperature cycler used. For the control reaction (600-bp target), use an annealing temperature of 55°C and an extension duration of 1 minute.

# Suggested PCR Program for RoboCycler® Temperature Cyclers

| Segment | Number of cycles | Temperature                       | Duration                    |
|---------|------------------|-----------------------------------|-----------------------------|
| 1       | 1                | 95°C°                             | 2 minutes                   |
| 2       | 30 <sup>b</sup>  | 95°C                              | 1 minute                    |
|         |                  | Primer $T_m - 5^{\circ}C^{\circ}$ | 1 minute                    |
|         |                  | 72°C                              | 1 minute (≤1-kb targets) or |
|         |                  |                                   | 1 minute/kb (>1-kb targets) |
| 3       | 1                | 72°C                              | 10 minutes                  |

<sup>&</sup>lt;sup>a</sup> Denaturing temperatures above 95°C are recommended only for GC-rich templates.

# Suggested PCR Program for Single-Block Temperature Cyclers

| Segment | Number of cycles | Temperature                 | Duration                    |
|---------|------------------|-----------------------------|-----------------------------|
| 1 °     | 1                | 95°C⁵                       | 2 minutes                   |
| 2       | 30∘              | 95°C                        | 30 seconds                  |
|         |                  | Primer $T_m - 5^{\circ}C^d$ | 30 seconds                  |
|         |                  | 72°C                        | 1 minute (≤1-kb targets) or |
|         |                  |                             | 1 minute/kb (>1-kb targets) |
| 3       | 1                | 72°C                        | 10 minutes                  |

<sup>&</sup>lt;sup>a</sup> Certain thermocyclers may require the removal of segment 1. Optimized cycling parameters are not necessarily transferable between thermal cyclers designed by different manufacturers; therefore, each manufacturer's recommendations for optimal cycling parameters should be consulted.

<sup>&</sup>lt;sup>b</sup> Low mutation frequencies (0–4.5 mutations per kb) can be achieved by reducing the cycle number (see Cycle Number in Preprotocol Considerations).

<sup>&</sup>lt;sup>c</sup> The annealing temperature may be lowered further if necessary to obtain optimal results. Typically annealing temperatures will range between 55° and 72°C.<sup>19</sup>

<sup>&</sup>lt;sup>b</sup> Denaturing temperatures above 95°C are recommended only for GC-rich templates.

<sup>&</sup>lt;sup>c</sup> Low mutation frequencies (0–4.5 mutations per kb) can be achieved by reducing the cycle number (see Cycle Number in Preprotocol Considerations).

<sup>&</sup>lt;sup>d</sup> The annealing temperature may be lowered further if necessary to obtain optimal results. Typically annealing temperatures will range between 55° and 72°C.<sup>19</sup>

7. Quantitate the PCR product yield. Electrophorese 1–10 μl of each amplification reaction along with 2.5 μl (50 ng) of the 1.1-kb gel standard on a 1% agarose gel. Estimate the PCR product yield by comparing the intensities of the PCR product bands with the 1.1-kb gel standard. Comparisons can be made either by visual inspection, or for a more accurate estimate, by using an imaging system. The PCR product yield should be within the range that provides the recommended fold amplification to achieve the expected mutation frequencies listed in Table I.

Note The expected mutation frequencies are typically achieved when the PCR yield of a 10-µl sample is between 100 ng and 2 μg, which corresponds to a yield of between 500 ng and 10 μg for a 50-μl reaction. If the mutation frequency is to be calculated using the graphs in the Appendix rather than the guidelines in Table I, it is recommended that actual PCR product yield is determined from a DNA standard curve. To prepare a standard curve, customers use their own DNA standard, consisting of linear double-stranded DNA of known concentration and of similar size to the sample amplicon. Four known amounts (100 ng, 500 ng, 1000 ng and 2000 ng) of the DNA standard should be electrophoresed adjacent to 10 µl of the PCR product to be analyzed. A densitometry program should be used to quantify the DNA in each standard lane so that a calibration curve can be constructed. PCR product yield (per 10 µl) can then be determined from the density of the PCR product band by extrapolation from the DNA standard curve.

#### 8. Purify the PCR product.

If the amount of the initial DNA template is less than 50 ng per 50  $\mu$ l reaction and the same plasmid DNA is used in the following EZClone reaction, use a commercial PCR purification kit (e.g., Stratagene's StrataPrep® PCR Purification Kit, Catalog #400771 or #400773).

If the amount of the initial DNA template is more than 50 ng or if a different plasmid DNA will be used in the following EZClone reaction, use a commercial DNA gel extraction kit (e.g., Stratagene's StrataPrep DNA Gel Extraction Kit, Catalog #400766 or #400768).

9. Quantitate the purified PCR product by electrophoresing 1–10 μl of each amplification reaction on a 1% agarose gel. In a nearby lane, load 2.5 μl (50 ng) of the 1.1-kb gel standard. Estimate the purified PCR product yield by comparing the intensities of the purified PCR product band with the 1.1-kb gel standard. Comparisons can be made either by visual inspection, or for a more accurate estimate, by using an imaging system.

#### **EZClone Reaction**

#### Notes

The plasmid DNA template used in the EZClone reaction may be the same or different than the original plasmid DNA used as template in the mutant megaprimer synthesis reaction, provided that the region targeted in the mutagenesis reaction is present in the plasmid.

Ensure that the plasmid DNA template is isolated from a dam+ E. coli strain. The majority of the commonly used E. coli strains are dam+. Plasmid DNA isolated from dam- strains (e.g. JM110 and SCS110) is not suitable.

To maximize temperature-cycling performance, Stratagene strongly recommends using thin-walled tubes, which ensure ideal contact with the temperature cycler's heat blocks. The following protocols were optimized using thin-walled tubes.

The EZClone solution has been shown to improve linear amplification, specifically of long, GC-rich, or difficult targets. Enhanced amplification efficiencies are observed when using between 2.5–3.5  $\mu$ l EZClone solution per 50- $\mu$ l reaction, with 3  $\mu$ l being optimal for most targets.

1. Prepare the control reaction as indicated below:

25 μl of the 2× EZClone enzyme mix 5 μl of the positive control plasmid (10 ng/μl) 250 ng megaprimer 3 μl of EZClone solution ddH<sub>2</sub>O to a final volume of 50 μl

2. Prepare the sample reaction(s) as indicated below:

25 μl of the 2× EZClone enzyme mix 50 ng of template plasmid 250 ng megaprimer (<1kb), or 500 ng for ≥1 kb megaprimer 3 μl of EZClone solution ddH<sub>2</sub>O to a final volume of 50 μl

3. If the thermal cycler to be used does not have a hot-top assembly, overlay each reaction with  $\sim$ 30  $\mu$ l of mineral oil.

4. Place each reaction in a temperature cycler and run the following PCR program. For the control reaction, use an extension time of 6 minutes.

#### Cycling Parameters for the GeneMorph® II EZClone Domain Mutagenesis Method for RoboCycler or Single-Block Temperature Cyclers

| Segment | Cycles | Temperature | Time                                       |
|---------|--------|-------------|--|
| 1       | 1      | 95°C        | 1 minute                                   |
| 2       | 25     | 95°C        | 50 seconds                                 |
|         |        | 60°C        | 50 seconds                                 |
|         |        | 68°C        | 2 minute/kb of plasmid length <sup>o</sup> |

<sup>&</sup>lt;sup>a</sup> For example, a 5-kb plasmid requires 10 minutes at 68°C per cycle.

5. Following temperature cycling, place the reaction on ice for 2 minutes to cool the reaction to  $\leq 37^{\circ}$ C.

#### **Digestion of the Amplification Products**

Note It is important to insert the pipet tip below the mineral oil overlay when adding the Dpn I restriction enzyme to the reaction tubes during the digestion step or when transferring the 1 µl of Dpn I-treated DNA to the transformation reaction. Stratagene suggests using specialized aerosol-resistant pipet tips, which are small and pointed, to facilitate this process.

- 1. Add 1 µl of *Dpn* I restriction enzyme (10 U/µl) directly to each amplification reaction below the mineral oil overlay using a small, pointed pipet tip.
- 2. Gently and thoroughly mix each reaction mixture by pipetting the solution up and down several times. Spin down the reaction mixtures in a microcentrifuge for 1 minute and immediately incubate each reaction at 37°C for 2 hours to digest the parental (i.e., the nonmutated) supercoiled dsDNA.

## Transformation of XL10-Gold® Ultracompetent Cells

**Notes** Please read the Transformation Guidelines before proceeding with the transformation protocol.

XL10-Gold cells are resistant to chloramphenicol and tetracycline. If the mutagenized plasmid contains only the  $Cam^R$  or  $Tet^R$  resistance marker, an alternative strain of competent cells must be used.

- 1. Gently thaw the XL10-Gold ultracompetent cells on ice. For each control and sample reaction to be transformed, aliquot 45 μl of the ultracompetent cells to a *prechilled* 14-ml BD Falcon polypropylene round-bottom tube.
- 2. Add 2  $\mu$ l of the XL10-Gold  $\beta$ -mercaptoethanol mix ( $\beta$ -ME) provided with the kit to the 45  $\mu$ l of cells. (Stratagene cannot guarantee highest efficiencies with  $\beta$ -ME from other sources.)
- 3. Swirl the contents of the tube gently. Incubate the cells on ice for 10 minutes, swirling gently every 2 minutes.
- 4. Transfer 1.5 μl of the *Dpn* I-treated DNA from each control and sample reaction to separate aliquots of the ultracompetent cells.

**Note** Carefully remove any residual mineral oil from the pipet tip before transferring the Dpn I-treated DNA to the transformation reaction.

As an optional control, verify the transformation efficiency of the XL10-Gold ultracompetent cells by adding 1  $\mu$ l of 0.01 ng/ $\mu$ l pUC18 control plasmid (dilute the control provided 1:10 in high-quality water) to a separate 45- $\mu$ l aliquot of the ultracompetent cells.

Swirl the transformation reactions gently to mix and incubate the reactions on ice for 10 minutes.

5. Preheat NZY<sup>+</sup> broth (see *Preparation of Media and Reagents*) in a 42°C water bath for use in step 8.

**Note** Transformation of XL10-Gold ultracompetent cells has been optimized using NZY+ broth.

6. Heat-pulse the tubes in a 42°C water bath for 30 seconds. The duration of the heat pulse is *critical* for obtaining the highest efficiencies. Do not exceed 42°C.

**Note** This heat pulse has been optimized for transformation in 14-ml BD Falcon polypropylene round-bottom tubes.

7. Incubate the tubes on ice for 2 minutes.

- 8. Add 0.5 ml of preheated (42°C) NZY+ broth to each tube, then incubate the tubes at 37°C for 1 hour with shaking at 225–250 rpm.
- 9. Plate the appropriate volume of each transformation reaction, as indicated in the table below, on agar plates containing the appropriate antibiotic for the plasmid vector.

For the mutagenesis and transformation controls, spread cells on LB–ampicillin agar plates containing 80  $\mu$ g/ml X-gal and 20 mM IPTG (see *Preparation of Media and Reagents*).

#### **Transformation reaction plating volumes**

| Reaction Type                        | Volume to Plate                     |
|--------------------------------------|-------------------------------------|
| Positive mutagenesis control plasmid | 10 μl (in 200 μl of NZY+ broth)*    |
| pUC18 transformation control         | 5 μl (in 200 μl of NZY+ broth)*     |
| Sample mutagenesis                   | 20 and 200 μl on each of two plates |

<sup>\*</sup> Place a 200- $\mu$ l pool of NZY<sup>+</sup> broth on the agar plate, pipet the 5  $\mu$ l of the transformation reaction into the pool, then spread the mixture.

10. Incubate the transformation plates at 37°C for >16 hours.

#### **Expected Results**

#### **Expected Results for the Control Transformations**

The positive mutagenesis control reaction monitors the introduction of mutations into the lacZ target gene. The expected colony number from the transformation of the positive mutagenesis control reaction is >50 colonies. Under highly mutagenic PCR conditions (i.e., 30 PCR cycles using 1 ng of positive control template), >25% of the transformants appear white (phenotypic mutants) as compared to <1% white colonies for the non-mutagenized transformed control plasmid, when plated on agar plates containing IPTG and X-gal. White colonies indicate that random mutations made within the lacZ gene have destroyed  $\beta$ -galactosidase activity, and that the EZClone reaction was successful. Colonies that appear blue indicate that either the random mutations made to the megaprimer do not result in a phenotypic change from blue- to white-colored colonies, or that the Dpn I digestion was not 100% efficient.

**Notes** Both true blue and light blue colonies are counted as blue colonies.

White colonies appearing on the control transformation plate indicate that random mutations were made in the portion of the lacZ gene that results in a phenotypic change from blue to white colonies. The expected percentage of white colonies does not represent the overall genotypic mutation rate, which typically can be much higher than the phenotypic rate.

If transformation of the pUC18 control plasmid was performed, >100 colonies should be observed (transformation efficiency >10 $^9$  cfu/ $\mu$ g) with >98% of the colonies having the blue phenotype.

#### **Expected Results for Sample Transformations**

The colony number will vary depending on experimental conditions, including the volume plated and plasmid DNA size. For suggestions on increasing colony number, see *Troubleshooting*. The insert of interest should be sequenced to verify that selected clones contain the desired mutation(s).

#### **TRANSFORMATION GUIDELINES**

#### **Storage Conditions**

Ultracompetent cells are sensitive to even small variations in temperature and must be stored at the bottom of a  $-80^{\circ}$ C freezer. Transferring tubes from one freezer to another may result in a loss of efficiency. Ultracompetent cells should be placed at  $-80^{\circ}$ C directly from the dry ice shipping container.

#### Aliquoting Cells

When aliquoting, keep ultracompetent cells on ice at all times. It is essential that the 14-ml BD Falcon polypropylene round-bottom tubes are placed on ice before the cells are thawed and that the cells are aliquoted directly into the chilled tubes. It is also important to use at least 40  $\mu$ l of ultracompetent cells/transformation.

#### Use of 14-ml BD Falcon Polypropylene Round-Bottom Tubes

It is important that 14-ml BD Falcon polypropylene round-bottom tubes are used for the transformation protocol, since other tubes may be degraded by the  $\beta$ -mercaptoethanol used in the transformation protocol. In addition, the duration of the heat-pulse step is critical and has been optimized specifically for the thickness and shape of these tubes.

#### Use of $\beta$ -Mercaptoethanol

β-mercaptoethanol (β-ME) has been shown to increase transformation efficiency. The XL10-Gold β-mercaptoethanol mix provided in this kit is diluted and ready to use. For optimum efficiency, use 2  $\mu$ l of the β-ME mix. (Stratagene cannot guarantee highest efficiencies with β-ME from other sources.)

## Length and Temperature of the Heat Pulse

There is a defined window of highest efficiency resulting from the heat pulse during transformation. Optimal efficiencies are observed when cells are heat pulsed for 30 seconds. Heat pulsing for at least 30 seconds is recommended to allow for slight variations in the length of incubation. Efficiencies decrease when the duration of the heat pulse is <30 seconds or >40 seconds. Do not exceed 42°C.

## **Preparing the Agar Plates for Color Screening**

To prepare the LB agar plates for blue—white color screening, add 80 µg/ml of 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal), 20 mM isopropyl-1-thio- $\beta$ -D-galactopyranoside (IPTG), and the appropriate antibiotic to the LB agar. Alternatively, 100 µl of 10 mM IPTG and 100 µl of 2% X-gal can be spread on the LB agar plates 30 minutes prior to plating the transformations. Prepare the IPTG in sterile dH<sub>2</sub>O; prepare the X-gal in dimethylformamide (DMF). Do not mix the IPTG and X-gal before pipetting them onto the plates because these chemicals may precipitate.

## **TROUBLESHOOTING**

## **Mutagenesis Protocol Troubleshooting**

| Observation                           | Suggestion(s)  |
|---------------------------------------|--|
| No product or low yield of megaprimer | Ensure that extension times are of sufficient length. Increase extension time to 2 minutes/kb of PCR target.   |
|                                       | Ensure that the annealing temperature is not too high. Lower the annealing temperature in 5°C increments.  |
|                                       | Consider the GC content or secondary structure. For high GC content or secondary structure, use higher denaturing temperatures (94–98°C) (see also Reference 20). Use cosolvents such as DMSO in a 1–10% (v/v) final concentration or glycerol in a 5–20% (v/v) final concentration.   |
|                                       | Ensure that the primer concentration is sufficient. Use primer concentrations between 0.1 and 0.5 $\mu$ M (generally 100–250 ng for typical 18- to 25-mer oligonucleotide primers in a 100- $\mu$ l reaction volume).  |
|                                       | Evaluate primers. Use high-quality primers. Check the melting temperature, purity, GC content, and length of the primers.  |
|                                       | Check the ionic strength of the reaction mixture. If ionic strength is high, remove extraneous salts from the PCR primers and DNA preparations.  |
|                                       | Ensure that the amount of Mutazyme II DNA polymerase* is sufficient. The amount of Mutazyme II DNA polymerase can be increased to 5 U/reaction.  |
|                                       | Ensure that there is adequate heat exchange between the reaction tubes and the thermal cycler. Use thin-walled PCR tubes for Stratagene's thermal cyclers (i.e., the RoboCycler Gradient 96 temperature cycler, the RoboCycler 96 temperature cycler, the RoboCycler Gradient 40 temperature cycler, and the RoboCycler 40 temperature cycler). These PCR tubes are optimized to ensure ideal contact with the multiblock design to permit more efficient heat transfer and to maximize temperature cycling performance. |
|                                       | Increase the number of cycles to greater than 30.  |
|                                       | Avoid multiple freeze-thaw cycles for the dNTP mix. Thaw the dNTP mix once, prepare single-use aliquots, and store the aliquots at –20°C. Do not subject the dNTP mix to multiple freeze-thaw cycles.  |
| Multiple bands                        | Ensure that the primer annealing temperature is sufficient. Increase the annealing temperature in 5°C increments.  |
|                                       | Multiple bands can be caused by nonspecific primer—template annealing. Use Perfect Match® PCR enhancer to improve PCR product specificity.   |
| Artifactual smears                    | Ensure that the amount of Mutazyme II DNA polymerase is not excessive. Decrease the amount of Mutazyme II DNA polymerase.  |
|                                       | Ensure that the extension time is not too long. Reduce the extension time.   |
|                                       | If smearing occurs in sequential PCR reactions, reduce the amount of PCR product used as template.   |

<sup>\*</sup> Mutazyme II DNA polymerase is not sold separately.

## **TROUBLESHOOTING CONTINUED**

## **EZClone Reaction Troubleshooting**

| Observation  | Suggestion(s)  |
|--|--|
| Low transformation<br>efficiency or low colony<br>number | Ensure that excess mineral oil is not transferred into the transformation reaction when pipetting the <i>Dpn</i> I-treated DNA. Using the smallest pipet tips available, insert the pipet tip completely below the mineral layer overlay and clear the pipet tip while submerged beneath the mineral oil overlay before collecting the sample. |
|  | Ensure that sufficient mutant DNA is synthesized in the reaction. Increase the amount of the $Dpn$ I-treated DNA used in the transformation reaction to 4 $\mu$ l.   |
|  | Visualize the recipient DNA template on a gel to verify the quantity and quality. Nicked or linearized plasmid DNA will not generate complete circular product. Verify that the template DNA is at least 80% supercoiled.  |
|  | It is not uncommon to observe low numbers of colonies, depending on the size of the donor plasmid. Most of the colonies that do appear, however, will contain mutagenized plasmid.   |
|  | Different thermal cyclers may contribute to variations in ramping efficiencies. Adjust the cycling parameters and repeat the protocol for the sample reactions.  |
|  | Ensure that supercompetent cells are stored at the bottom of a $-80^{\circ}$ C freezer immediately upon arrival (see also <i>Transformation Guidelines</i> ).  |
|  | For the control reaction, verify that the agar plates were prepared correctly. See<br>Preparation of Media and Reagents, and follow the recommendations for IPTG and X-Gal concentrations carefully.   |
|  | For best visualization of the blue ( $\beta$ -gal <sup>+</sup> ) phenotype in the control reaction, plates must be incubated for at least 16 hours at 37°C.  |
| Low mutagenesis efficiency                               | Add the Dpn I restriction enzyme below the mineral oil overlay in the digestion step and ensure proper mixing of all components in the reaction especially the Dpn I.  |
|  | Allow sufficient time for the <i>Dpn</i> I to completely digest the parental template; repeat the digestion if too much DNA template was present.  |
|  | Stratagene recommends setting up an initial sample reaction using 250 ng of megaprimer for primers <1 kb and 500 ng of megaprimer for primers ≥1 kb. If this initial reaction is unsuccessful, set up a series of sample reactions using various concentrations of megaprimer while keeping the template concentration constant.               |
|  | Avoid subjecting the EZClone enzyme mix to multiple freeze-thaw cycles. Store at $-20^{\circ}$ C upon receipt. Store the $2\times$ EZClone enzyme mix at $4^{\circ}$ C after thawing. Once thawed, full activity is guaranteed for 3 months.   |

#### PREPARATION OF MEDIA AND REAGENTS

#### LB Agar (per Liter)

10 g of NaCl

10 g of tryptone

5 g of yeast extract

20 g of agar

Add deionized H<sub>2</sub>O to a final volume of

1 liter

Adjust pH to 7.0 with 5 N NaOH

Autoclave

Pour into petri dishes (~25 ml/100-mm plate)

#### LB-Ampicillin Agar (per Liter)

(Use for reduced satellite colony formation)

1 liter of LB agar

Autoclave

Cool to 55°C

Add 100 mg of filter-sterilized ampicillin Pour into petri dishes (~25 ml/100-mm plate)

## NZY<sup>+</sup> Broth (per Liter)

10 g of NZ amine (casein hydrolysate)

5 g of yeast extract

5 g of NaCl

Add deionized H<sub>2</sub>O to a final volume

of 1 liter

Adjust to pH 7.5 using NaOH

Autoclave

Add the following filer-sterilized

supplements prior to use:

12.5 ml of 1 M MgCl<sub>2</sub>

12.5 ml of 1 M MgSO<sub>4</sub>

20 ml of 20% (w/v) glucose (or 10 ml

of 2 M glucose)

#### **TE Buffer**

10 mM Tris-HCl (pH 7.5) 1 mM EDTA

## **Agar Plates for Blue-White Color Screening**

Prepare LB agar as indicated above. When adding the antibiotic, also add 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal) to a final concentration of 80 µg/ml [prepared in dimethylformamide (DMF)] and isopropyl-1-thio- $\beta$ -D-galactopyranoside (IPTG) to a final concentration of 20 mM (prepared in sterile dH<sub>2</sub>O). Alternatively, 100 µl of 10 mM IPTG and 100 µl of 2% X-gal may be spread on solidified LB agar plates 30 minutes prior to plating the transformations. (For consistent color development across the plate, pipet the X-gal and the IPTG into a 100-µl pool of SOC medium and then spread the mixture across the plate. Do not mix the IPTG and X-gal before pipetting them into the pool of medium because a precipitate may form.) Spreading the IPTG and X-gal on the plate surface produces darker blue colonies compared to the pale blue colonies produced when IPTG and X-gal are added to the medium prior to pouring).

#### **APPENDIX: HOW TO CALCULATE MUTATION FREQUENCY**

The mutation frequency is controlled by adjusting the initial amount of target DNA in an amplification reaction or the number of thermal cycles as explained by the following equations.

The mutation frequency of an amplification reaction is determined by the formula:

$$Mutation\ frequency = error\ rate \times d \tag{1}$$

where *mutation frequency* is expressed as mutations/kb, *error rate* is the error rate of the DNA polymerase in errors/(kb·duplication), and d is the number of duplications during PCR.

The variable d can be calculated from the following equation:

$$2^d = PCR \text{ yield/}initial \text{ amount of target}$$
 (2)

Note: In these calculations, initial amount of target refers to the amount of amplicon DNA present in the DNA template, and not the total amount of plasmid DNA added to the reaction. As an example, to mutagenize a 1.0-kb target gene at a low mutation frequency, an initial target amount of 500 ng is recommended. For a 1.0-kb target gene that is an insert in a 3.0-kb plasmid (the total construct is 4.0 kb), 2  $\mu$ g of the plasmid construct should be added to the reaction to provide 500 ng of target DNA.

Solving for d, we obtain

$$d = \log_{10}(PCR \text{ yield/initial target amount)/}\log_{10}2.$$
 (3)

Equation (1) shows that mutation frequency is the product of DNA polymerase error rate and number of duplications. So, any change in d leads to a proportional change in the mutation frequency. An example of this relationship is given in Figure 2, which shows experimental data obtained using the GeneMorph II kit. Equation (3) shows that d depends on the ratio of total PCR product yield (per 50-ul reaction) to initial amount of target DNA. In the GeneMorph II kit, d (and hence mutation frequency) is varied by varying the initial amount of target DNA in the amplification reaction. For the same PCR yield, targets amplified from low amounts of target DNA undergo more duplications than targets amplified from high concentrations of target DNA. The more times a target is replicated, the more errors accumulate. Therefore, higher mutation frequencies are achieved simply by lowering input DNA template concentration. Conversely, lower PCR mutation frequencies can be achieved by using higher DNA template concentrations or fewer PCR cycles to limit the number of target duplications.




Figure 2 Relationship between mutation frequency and duplications.

The observed mutation frequencies produced by the GeneMorph II kit for varying amounts of lacZ input DNA is shown in Table 1. These target amounts have given a total PCR product yield (per 50- $\mu$ l reaction) of 200 ng to 6  $\mu$ g.

Customers interested in determining the mean mutation frequency achieved in their amplification reaction can do so by determining the *d* value; *d* values are calculated from equation (3) after quantifying PCR product yield using the recommendations (standard curve) described in step 6 in *Protocol* section. Expected average mutation frequency (mutations per kb) can then be determined by extrapolation from the above graph (see Figure 2).

#### REFERENCES

- 1. Miyazaki, K. (2003) Methods Mol Biol 231:23-8.
- 2. Miyazaki, K. and Takenouchi, M. (2002) Biotechniques 33(5):1033-8.
- Daugherty, P. S., Chen, G., Iverson, B. L. and Georgiou, G. (2000) Proc Natl Acad Sci U S A 97(5):2029-34.
- 4. Vartanian, J. P., Henry, M. and Wain-Hobson, S. (1996) Nucleic Acids Res 24(14):2627-31.
- 5. Shafikhani, S., Siegel, R. A., Ferrari, E. and Schellenberger, V. (1997) Biotechniques 23(2):304-10.
- Cherry, J. R., Lamsa, M. H., Schneider, P., Vind, J., Svendsen, A. et al. (1999) Nat Biotechnol 17(4):379-84.
- 7. Wan, L., Twitchett, M. B., Eltis, L. D., Mauk, A. G. and Smith, M. (1998) Proc Natl Acad Sci U S A 95(22):12825-31.
- 8. You, L. and Arnold, F. H. (1996) Protein Eng 9(1):77-83.
- 9. Cline, J. and Hogrefe, H. H. (2000) Strategies 13(4):157-161.
- 10. Nelson, M. and McClelland, M. (1992) Methods Enzymol 216:279-303.
- 11. Jerpseth, B., Callahan, M. and Greener, A. (1997) Strategies 10(2):37-38.
- 12. Wnendt, S. (1994) Biotechniques 17(2):270, 272.
- 13. Kohler, S. W., Provost, G. S., Kretz, P. L., Dycaico, M. J., Sorge, J. A. et al. (1990) Nucleic Acids Res 18(10):3007-13.
- 14. Kretz, P. L., Kohler, S. W. and Short, J. M. (1991) J Bacteriol 173(15):4707-16.
- 15. Raleigh, E. A. and Wilson, G. (1986) Proc Natl Acad Sci U S A 83(23):9070-4.
- 16. Jerpseth, B., Greener, A., Short, J. M., Viola, J. and Kretz, P. L. (1992) Strategies 5(3):81–83.
- 17. Bullock, W. O., Fernandez, J. M. and Short, J. M. (1987) Biotechniques 5(4):376–378.
- 18. Greener, A. and Jerpseth, B. (1993) Strategies 6(2):57.
- Innis, M. A., Gelfand, D. H., Sninsky, J. J. and White, T. J. (1990). PCR Protocols: A Guide to Methods and Applications. Academic Press, New York.
- 20. Sarkar, G., Kapelner, S. and Sommer, S. S. (1990) Nucleic Acids Res 18(24):7465.

#### **ENDNOTES**

GeneMorph®, Mutazyme®, Perfect Match®, *PfuUltra®*, StrataPrep®, RoboCycler®, and XL10-Gold® are registered trademarks of Stratagene in the United States.

## **MSDS INFORMATION**

The Material Safety Data Sheet (MSDS) information for Stratagene products is provided on Stratagene's website at <a href="http://www.stratagene.com/MSDS/">http://www.stratagene.com/MSDS/</a>. Simply enter the catalog number to retrieve any associated MSDS's in a print-ready format. MSDS documents are not included with product shipments.



## GeneMorph® II EZClone Domain Mutagenesis Kit

## **QUICK-REFERENCE PROTOCOL**

### **Mutation Frequency**

| Mutation frequency (mutations/kb) | Initial target quantity |  |
|-----------------------------------|-------------------------|--|
| 0–4.5 (low range)                 | 500–1000 ng             |  |
| 4.5–9 (medium range)              | 100–500 ng              |  |
| 9–16 (high range)                 | 0.1–100 ng              |  |

### **Equation**

 $d = log_{10}(PCR \text{ yield/initial target amount})/log_{10}2$ 

## **Mutant Megaprimer Synthesis**

Prepare the control and sample reaction(s) as indicated below:

| Control Reaction  | Sample Reaction  |
|---|--|
| <ul> <li>5 μl of 10× Mutazyme® II reaction buffer</li> <li>2 μl positive control plasmid (dilute the control provided 1:20 in high-quality water for a final concentration of 0.5 ng/μl)</li> <li>1 μl of positive control primer mix (125 ng/μl of each primer)</li> <li>1 μl of 40 mM dNTP mix (200 μM each final)</li> <li>40 μl of ddH<sub>2</sub>O</li> <li>1 μl of Mutazyme II DNA polymerase (2.5 U/μl)</li> </ul> | 5 μl of 10× Mutazyme® II reaction buffer x μl template (see Table above for recommended amount) x μl of sample primers (125 ng/μl of each primer) 1 μl of 40 mM dNTP mix (200 μM each final) x μl of ddH <sub>2</sub> O for a final reaction volume of 50 μl 1 μl of Mutazyme II DNA polymerase (2.5 U/μl) |

Overlay each reaction with 30  $\mu$ l of mineral oil.

Cycle each reaction using the cycling parameters outlined in the following tables:

## Suggested PCR Program for RoboCycler® Temperature Cyclers

| Segment | Number of cycles | Temperature                 | Duration   |
|---------|------------------|-----------------------------|--|
| 1       | 1                | 95°C                        | 2 minutes  |
| 2       | 30°              | 95°C                        | 1 minute   |
|         |                  | Primer T <sub>m</sub> - 5°C | 1 minute   |
|         |                  | 72°C                        | 1 minute (≤1-kb targets) or<br>1 minute/kb (>1 kb targets) |
| 3       | 1                | 72°C                        | 10 minutes   |

Low mutation frequencies (0–4.5 mutations per kb) can be achieved by reducing the cycle number (see Cycle Number in Preprotocol Considerations).

## **Suggested PCR Program for Single-Block Temperature Cyclers**

| Segment | Number of cycles | Temperature               | Duration   |
|---------|------------------|---------------------------|--|
| 1       | 1                | 95°C                      | 2 minutes  |
| 2       | 30°              | 95°C                      | 30 seconds   |
|         |                  | Primer $T_m - 5^{\circ}C$ | 30 seconds   |
|         |                  | 72°C                      | 1 minute (≤1-kb targets) or<br>1 minute/kb (>1 kb targets) |
| 3       | 1                | 72°C                      | 10 minutes   |

Low mutation frequencies (0–4.5 mutations per kb) can be achieved by reducing the cycle number (see Cycle Number in Preprotocol Considerations).

Quantitate the PCR yield by running 2.5  $\mu$ l of the PCR product and 2.5  $\mu$ l (50 ng) of the 1.1 kb gel standard on a 1% agarose gel and compare the two bands.

Purify the PCR product.

Quantitate the purified megaprimer using the 1.1 kb gel standard.

#### **EZClone Reaction**

Prepare the control and sample reaction(s) as indicated below:

| Control Reaction  | Sample Reaction                                |  |
|---|--|--|
| 25 μl of 2× EZClone enzyme mix                          | 25 μl of 2× EZClone enzyme mix                 |  |
| 5 μl (50 ng) of the positive control plasmid (10 ng/μl) | 50 ng of template plasmid                      |  |
| 250 ng megaprimer                                       | 250 ng megaprimer (<1kb), or 500 ng for > 1 kb |  |
| 3 μl of EZClone solution                                | megaprimer                                     |  |
| ddH <sub>2</sub> O to a final volume of 50 μl           | 3 μl of EZClone solution                       |  |
|   | ddH <sub>2</sub> O to a final volume of 50 μl  |  |

Overlay each reaction with 30  $\mu$ l of mineral oil.

Cycle each reaction using the cycling parameters outlined in the following table:

| Segment | Cycles | Temperature | Time                          |
|---------|--------|-------------|-------------------------------|
| 1       | 1      | 95°C        | 1 minute                      |
| 2       | 25     | 95°C        | 50 seconds                    |
|         |        | 60°C        | 50 seconds                    |
|         |        | 68°C        | 2 minute/kb of plasmid length |

Cool the reactions to ≤37°C by placing them on ice.

Add 1  $\mu$ l of Dpn I restriction enzyme below the mineral oil overlay.

Gently and thoroughly mix each reaction, spin the tube in a microcentrifuge for 1 minute, and immediately incubate at 37°C for 2 hours to digest the parental supercoiled dsDNA.

Transform 1.5  $\mu$ l of the *Dpn* I-treated DNA from each control and sample reaction into separate 45- $\mu$ l aliquots of XL10-Gold ultracompetent cells.